Cryopreserved mesenchymal stromal cells maintain potency in a retinal ischemia/reperfusion injury model: Toward an off-the-shelf therapy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Gramlich, Oliver W ^a,b   Burand, Anthony J ^a,c   Brown, Alex J ^a,c   Deutsch, Riley J ^a,c   Kuehn, Markus H ^a,b   Ankrum, James A ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b Center for Prevention and Treatment of Visual Loss   (United States)

^c IA United States   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CRYOPRESERVATION; CYTOLOGY; DISEASE MODEL; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MOUSE; PROCEDURES; REPERFUSION INJURY; RETINA DISEASE; RETINA GANGLION CELL;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CRYOPRESERVATION; DISEASE MODELS, ANIMAL; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; REPERFUSION INJURY; RETINAL DISEASES; RETINAL GANGLION CELLS;

EID: 84971325635     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26463     Document Type: Article

References (56)

1. Umezawa, H., Suhara, Y., Takita, T., & Maeda, K. Purification of bleomycins. The Journal of antibiotics 19, 210-215 (1966).
2. Umezawa, H., Maeda, K., Takeuchi, T., & Okami, Y. New antibiotics, bleomycin A and B. The Journal of antibiotics 19, 200-209 (1966).
3. Gordon, L. I., et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31, 684-691, doi: 10.1200/JCO.2012.43.4803 (2013).
4. Albers, P., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26, 2966-2972, doi: 10.1200/JCO.2007.12.0899 (2008).
5. Murad, A. M., Triginelli, S. A., & Ribalta, J. C. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 12, 55-59 (1994).
6. Hecht, S. M. Bleomycin: new perspectives on the mechanism of action. Journal of natural products 63, 158-168 (2000).
7. Sugiura, Y., Suzuki, T., Kuwahara, J., & Tanaka, H. On the mechanism of hydrogen peroxide-, superoxide-, and ultraviolet lightinduced DNA cleavages of inactive bleomycin-iron (III) complex. Biochemical and biophysical research communications 105, 1511-1518 (1982).
8. Miura, T. The peroxidase activity of bleomycin-Fe3+ is associated with damage to biological components. Journal of biochemistry 157, 217-224, doi: 10.1093/jb/mvu063 (2015).
9. Carver, J. R., et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25, 3991-4008, doi: 10.1200/JCO.2007.10.9777 (2007).
10. Cavallo, C., et al. Comparison of alternative mesenchymal stem cell sources for cell banking and musculoskeletal advanced therapies. Journal of cellular biochemistry 112, 1418-1430, doi: 10.1002/jcb.23058 (2011).
11. Moroni, L., & Fornasari, P. M. Human mesenchymal stem cells: a bank perspective on the isolation, characterization and potential of alternative sources for the regeneration of musculoskeletal tissues. J Cell Physiol 228, 680-687, doi: 10.1002/jcp.24223 (2013).
12. Dominici, M., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317, doi: 10.1080/14653240600855905 (2006).
13. Ho, A. D., Wagner, W., & Franke, W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 10, 320-330, doi: 10.1080/14653240802217011 (2008).
14. Nicolay, N. H., Lopez Perez, R., Debus, J., & Huber, P. E. Mesenchymal stem cells-A new hope for radiotherapy-induced tissue damage?. Cancer letters 366, 133-140, doi: 10.1016/j.canlet.2015.06.012 (2015).
15. Usunier, B., Benderitter, M., Tamarat, R., & Chapel, A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem cells international 2014, 340257, doi: 10.1155/2014/340257 (2014).
16. Wang, C., et al. Inhibition of Wnt/beta-catenin signaling promotes epithelial differentiation of mesenchymal stem cells and repairs bleomycin-induced lung injury. American journal of physiology. Cell physiology 307, C234-244, doi: 10.1152/ajpcell.00366.2013 (2014).
17. Ortiz, L. A., et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proceedings of the National Academy of Sciences of the United States of America 100, 8407-8411, doi: 10.1073/ pnas.1432929100 (2003).
18. Nicolay, N. H., et al. Mesenchymal stem cells are resistant to carbon ion radiotherapy. Oncotarget 6, 2076-2087 (2015).
19. Nicolay, N. H., et al. Mesenchymal stem cells retain their defining stem cell characteristics after exposure to ionizing radiation. International journal of radiation oncology, biology, physics 87, 1171-1178, doi: 10.1016/j.ijrobp.2013.09.003 (2013).
20. Srour, N., & Thebaud, B. Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review. Stem cells translational medicine 4, 1500-1510, doi: 10.5966/sctm.2015-0121 (2015).
21. Lan, Y. W., et al. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem cell research & therapy 6, 97, doi: 10.1186/s13287-015-0081-6 (2015).
22. Dorr, R. T. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Seminars in oncology 19, 3-8 (1992).
23. Oken, M. M., Crooke, S. T., Elson, M. K., Strong, J. E., & Shafer, R. B. Pharmacokinetics of bleomycin after im administration in man. Cancer treatment reports 65, 485-489 (1981).
24. Li, J., Law, H. K., Lau, Y. L., & Chan, G. C. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. British journal of haematology 127, 326-334, doi: 10.1111/j.1365-2141.2004.05200.x (2004).
25. Liang, W., Xia, H., Li, J., & Zhao, R. C. Human adipose tissue derived mesenchymal stem cells are resistant to several chemotherapeutic agents. Cytotechnology 63, 523-530, doi: 10.1007/s10616-011-9374-5 (2011).
26. Nicolay, N. H., et al. Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft ? [et al.] 190, 1037-1045, doi: 10.1007/s00066-014-0686-1 (2014).
27. Nicolay, N. H., et al. Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin. Scientific reports 6, 20035, doi: 10.1038/srep20035 (2016).
28. Nicolay, N. H., et al. Mesenchymal stem cells exhibit resistance to topoisomerase inhibition. Cancer letters 374, 75-84, doi: 10.1016/j. canlet.2016.02.007 (2016).
29. Mueller, L. P., et al. Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem cells 24, 2753-2765, doi: 10.1634/stemcells.2006-0108 (2006).
30. Prendergast, A. M., Cruet-Hennequart, S., Shaw, G., Barry, F. P., & Carty, M. P. Activation of DNA damage response pathways in human mesenchymal stem cells exposed to cisplatin or gamma-irradiation. Cell cycle 10, 3768-3777, doi: 10.4161/cc.10.21.17972 (2011).
31. Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nature reviews. Cancer 8, 193-204, doi: 10.1038/nrc2342 (2008).
32. Sugrue, T., Brown, J. A., Lowndes, N. F., & Ceredig, R. Multiple Facets of The DNA Damage Response Contribute to the Radio-Resistance of Mouse Mesenchymal Stromal Cell Lines. Stem cells, doi: 10.1002/stem.1222 (2012).
33. Liang, W., Lu, C., Li, J., Yin, J. Q., & Zhao, R. C. p73alpha regulates the sensitivity of bone marrow mesenchymal stem cells to DNA damage agents. Toxicology 270, 49-56, doi: 10.1016/j.tox.2010.01.011 (2010).
34. Zeng, W., et al. Antioxidant treatment enhances human mesenchymal stem cell anti-stress ability and therapeutic efficacy in an acute liver failure model. Scientific reports 5, 11100, doi: 10.1038/srep11100 (2015).
35. Li, C. J., Sun, L. Y., & Pang, C. Y. Synergistic protection of N-Acetylcysteine and ascorbic acid 2-phosphate on human mesenchymal stem cells against mitoptosis, necroptosis and apoptosis. Scientific reports 5, 9819, doi: 10.1038/srep09819 (2015).
36. Schwartz, D. R., et al. The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. Proceedings of the National Academy of Sciences of the United States of America 96, 4680-4685 (1999).
37. Ferrando, A. A., Velasco, G., Campo, E., & Lopez-Otin, C. Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer research 56, 1746-1750 (1996).
38. Sebti, S. M., Jani, J. P., Mistry, J. S., Gorelik, E., & Lazo, J. S. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer research 51, 227-232 (1991).
39. Akiyama, S., Ikezaki, K., Kuramochi, H., Takahashi, K., & Kuwano, M. Bleomycin-resistant cells contain increased bleomycinhydrolase activities. Biochemical and biophysical research communications 101, 55-60 (1981).
40. Jin, Y. W., et al. Comprehensive analysis of time-And dose-dependent patterns of gene expression in a human mesenchymal stem cell line exposed to low-dose ionizing radiation. Oncology reports 19, 135-144 (2008).
41. Williams, A. R., & Hare, J. M. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circulation research 109, 923-940, doi: 10.1161/CIRCRESAHA.111.243147 (2011).
42. Muraglia, A., Cancedda, R., & Quarto, R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. Journal of cell science 113 (Pt 7), 1161-1166 (2000).
43. Jang, E. J., et al. TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-Activator TAZ. British journal of pharmacology 165, 1584-1594, doi: 10.1111/j.1476-5381.2011.01664.x (2012).
44. Zhang, F., et al. Mobilization of bone marrow cells by CSF3 protects mice from bleomycin-induced lung injury. Respiration; international review of thoracic diseases 82, 358-368, doi: 10.1159/000328762 (2011).
45. Bitencourt, C. S., et al. Hyaluronidase recruits mesenchymal-like cells to the lung and ameliorates fibrosis. Fibrogenesis & tissue repair 4, 3, doi: 10.1186/1755-1536-4-3 (2011).
46. Braun, R. K., et al. Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion. Cytotherapy 18, 536-545, doi: 10.1016/j.jcyt.2016.01.010 (2016).
47. Huang, K., et al. Conversion of bone marrow mesenchymal stem cells into type II alveolar epithelial cells reduces pulmonary fibrosis by decreasing oxidative stress in rats. Molecular medicine reports 11, 1685-1692, doi: 10.3892/mmr.2014.2981 (2015).
48. Yu, S. H., et al. Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF-gamma and TGF-beta. Cell biochemistry and function 33, 356-366, doi: 10.1002/ cbf.3118 (2015).
49. Shen, Q., et al. Paracrine factors from mesenchymal stem cells attenuate epithelial injury and lung fibrosis. Molecular medicine reports 11, 2831-2837, doi: 10.3892/mmr.2014.3092 (2015).
50. Chinnadurai, M., et al. Bleomycin, neocarzinostatin and ionising radiation-induced bystander effects in normal diploid human lung fibroblasts, bone marrow mesenchymal stem cells, lung adenocarcinoma cells and peripheral blood lymphocytes. International journal of radiation biology 87, 673-682, doi: 10.3109/09553002.2010.549536 (2011).
51. Torsvik, A., & Bjerkvig, R. Mesenchymal stem cell signaling in cancer progression. Cancer treatment reviews 39, 180-188, doi: 10.1016/j.ctrv.2012.03.005 (2013).
52. Antunes, M. A., Laffey, J. G., Pelosi, P., & Rocco, P. R. Mesenchymal stem cell trials for pulmonary diseases. Journal of cellular biochemistry 115, 1023-1032, doi: 10.1002/jcb.24783 (2014).
53. Chambers, D. C., et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology 19, 1013-1018, doi: 10.1111/resp.12343 (2014).
54. Henry, E., et al. Adult Lung Spheroid Cells Contain Progenitor Cells and Mediate Regeneration in Rodents With Bleomycin-Induced Pulmonary Fibrosis. Stem cells translational medicine 4, 1265-1274, doi: 10.5966/sctm.2015-0062 (2015).
55. Jun, D., et al. The pathology of bleomycin-induced fibrosis is associated with loss of resident lung mesenchymal stem cells that regulate effector T-cell proliferation. Stem cells 29, 725-735, doi: 10.1002/stem.604 (2011).
56. Wagner, W., et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Experimental hematology 33, 1402-1416, doi: 10.1016/j.exphem.2005.07.003 (2005).